Yi Li
liyi@simm.ac.cn
Chinese, English
Shanghai
University of Chinese Academy of Sciences
Medical School
  • 2009-09--2014-07 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • 2005-09--2009-07 Bachelor's: Wuhan University
  • 2022-06~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
  • 2018-12~2022-04 - University of Texas, USA - Postdoctoral Researcher
  • 2016-08~2018-11 - WuXi AppTec, Shanghai - Project Manager
  • 2014-07~2016-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Postdoctoral Researcher
  • 2009-09~2014-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - PhD
  • 2005-09~2009-07 - Wuhan University - Bachelor's
Innovative drug development for anti-tumor and metabolic diseases
  • Discovery, X-ray Crystallography, and Anti-Inflammatory Activity of Bromodomain-Containing Protein 4 (BRD4) Inhibitors Targeting a Distinct New Binding Site, Yi Li, 2022
  • Target-Based Small Molecule Drug Discovery towards Novel Therapeutics for Inflammatory Bowel Diseases, Yi Li, 2021
  • Applications of Asymmetric Petasis Reaction in the Synthesis of Chiral Amines, Yi Li, 2021
  • Water as a Direct Proton Source for Asymmetric Hydroarylation Catalyzed by a Rh(I)-Diene: Access to Nonproteinogenic beta(2)/gamma(2)/delta(2)-Amino Acid Derivatives, Yi Li, 2021
  • Discovery of Phenanthridine Analogues as Novel Chemical Probes Disrupting the Binding of DNA to ΔFosB Homodimers and ΔFosB/JunD Heterodimers, Yi Li, 2020
  • Rhodium-Catalyzed Enantioselective Alkenylation of Cyclic Ketimines: Synthesis of Multifunctional Chiral alpha,alpha-Disubstituted Allylic Amine Derivatives, Yi Li, 2018
  • Simple Open-Chain Phosphite-Olefin as Ligand for Rh-Catalyzed Asymmetric Arylation of Cyclic Ketimines: Enantioselective Access to gem-Diaryl alpha-Amino Acid Derivatives, Yi Li, 2016
  • Facile synthesis of acridines via Pd(0)-diphosphine complex-catalyzed tandem coupling/cyclization protocol, Yi Li, 2015
  • A highly diastereoselective Friedel-Crafts reaction of indoles with isatin-derived N-sulfinyl ketimines towards the efficient synthesis of chiral tetrasubstituted 3-indolyl-3-aminooxindoles, Yi Li, 2015
  • Rhodium-Catalyzed Asymmetric Tandem Cyclization for Efficient and Rapid Access to Underexplored Heterocyclic Tertiary Allylic Alcohols Containing a Tetrasubstituted Olefin, Yi Li, 2014
  • Simple sulfur-olefins as new promising chiral ligands for asymmetric catalysis, Yi Li, 2014
  • Rhodium-Catalyzed Highly Enantioselective Arylation of Cyclic Diketimines: Efficient Synthesis of Chiral Tetrasubstituted 1,2,5-Thiadiazoline 1,1-Dioxides, Yi Li, 2014
  • Identification of benzofuran-3-yl(phenyl)methanones as novel SIRT1 inhibitors: Binding mode, inhibitory mechanism and biological action, Yi Li, 2013
  • A new versatile approach to synthesise enantioenriched 3-hydroxyoxindoles, 1,3-dihydroisobenzofuran and 3-isochromanone derivatives by a rhodium-catalyzed asymmetric arylation-cyclization sequence, Yi Li, 2013
  • Lewis-Acid-Catalyzed Intramolecular Aza-Friedel-Crafts Reaction of N-tert-Butanesulfinyl Imines: Efficient Synthesis of Optically Active 9-Aminofluorene Derivatives, Yi Li, 2013
  • Lewis Acid Promoted Highly Diastereoselective Petasis Borono-Mannich Reaction: Efficient Synthesis of Optically Active beta,gamma-Unsaturated alpha-Amino Acids, Yi Li, 2012
  • Highly diastereoselective Friedel-Crafts reaction of arenes with N-tert-butanesulfinylimino ester towards the efficient synthesis of alpha-arylglycines, Yi Li, 2011
  • One-pot synthesis of furocoumarins via sequential Pd/Cu-catalyzed alkynylation and intramolecular hydroalkoxylation, Yi Li, 2010
Anti-Tumor Metabolic Diseases Drug Development Innovation Research Pharmaceuticals Oncology Metabolism Therapeutics Biochemistry

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.